Navigation Links
Scientists discover a molecular 'switch' in cancers of the testis and ovary
Date:7/31/2013

to improve survival rates when tumours are resistant to treatment. Having identified this 'on/off' switch, it will now be important to identify new drugs that can be used to keep it in the 'off' position."

Dr Matthew Murray, Academic Consultant in Paediatric Oncology, Addenbrooke's Hospital, Cambridge said: "The switch effect that we have discovered is present in all malignant germ cell tumours, whether they occur in males or females, young or old. Such a fundamental abnormality makes an excellent new target for treating these tumours."

Susanne Owers, Director of Fundraising at Addenbrooke's Charitable Trust, which funded this research, said: "We are delighted to have supported this study, which has identified a key protein that triggers this type of cancer. ACT funds clinical academic researchers, like Dr Murray and Prof Coleman, because they are perfectly positioned to understand the clinical problems, working closely with patients, an insight not available to all researchers. Studies like this have the potential to make a tangible difference to patients, by identifying targets for the development of new drugs which may improve survival and have less side-effects compared with standard chemotherapy treatments. By funding this research, ACT with the help of our supporters can make a powerful contribution, enabling ground breaking research to be performed."


'/>"/>

Contact: Genevieve Maul
gm349@admin.cam.ac.uk
44-012-237-65542
University of Cambridge
Source:Eurekalert

Page: 1 2

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Queens scientists seek vaccine for Pseudomonas infection
3. Scientists produce eye structures from human blood-derived stem cells
4. American Society of Plant Biologists honors early career women scientists
5. Brandeis scientists win prestigious prize for circadian rhythms research
6. Scientists discover new method of proton transfer
7. Salk scientists open new window into how cancers override cellular growth controls
8. WileyChina.com - Now Featuring Bespoke Pages for China’s Life Scientists
9. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
10. UGA scientists reveal genetic mutation depicted in van Goghs sunflower paintings
11. Genetic mutation depicted in van Goghs sunflower paintings revealed by scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... help scientists "build" new biological systems, Princeton University scientists ... enable the growth of living cells. The team ... nature, and the scientists showed that they can produce ... as proteins produced by nature,s own toolkit. ...
... ATHENS, Ohio (Jan. 6, 2011) Ohio University ... the bioengineering profession,s highest honor, the Fritz J. and ... Hood of Seattle, Washington, for his discoveries related to ... president and co-founder of the Institute for Systems Biology, ...
... at the University of Connecticut Health Center have identified a ... a predictor of heart attack. Their research, led by ... Cardiology Center, is published in the Jan. 11 issue of ... It found heart attack patients had elevated levels of the ...
Cached Biology News:Princeton scientists construct synthetic proteins that sustain life 2Princeton scientists construct synthetic proteins that sustain life 3DNA sequencing pioneer receives 2011 Russ Prize 2DNA sequencing pioneer receives 2011 Russ Prize 3
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... After litigating and negotiating patent infringement claims brought ... United States patent RE43,651 (the ,651 patent), ... United States without any admission or concession of ... a result of the parties, settlement, the US District Court ... dismissed the case without prejudice. Under the terms ...
(Date:8/26/2015)... Boston, MA (PRWEB) , ... August 26, 2015 , ... ... venue for Boston adult stem cell technology start-up company Asymmetrex to share ... widely the capabilities of a new biomarker for counting adult tissue stem cells. , ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... InterMune, Inc. (Nasdaq: ITMN ) today announced that ... InterMune, will present at Citi,s 4th Annual Biotech Day in ... EDT. To access a live audio webcast of the ... the investor relations page of InterMune,s corporate website at ...
... field of molecular diagnostics for lung cancer, has announced that Stephen ... Ph.D. has joined the company as Vice President of Operations and ... ... 2009 -- Allegro Diagnostics, a leader in the field of molecular ...
... Therapeutics, Inc. (Nasdaq: NLTX ), a leading company ... announced today that, in the course of reviewing the Investigational ... U.S. Food and Drug Administration (FDA) to support the initiation ... the treatment of acute heart failure, the FDA has placed ...
Cached Biology Technology:Allegro Diagnostics Expands Board and Executive Team 2Allegro Diagnostics Expands Board and Executive Team 3Allegro Diagnostics Expands Board and Executive Team 4Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure 2